Journal of Biological Chemistry,
Год журнала:
2018,
Номер
293(42), С. 16127 - 16141
Опубликована: Сен. 13, 2018
Microsatellite
expansions
cause
more
than
40
neurological
disorders,
including
Huntington's
disease,
myotonic
dystrophy,
and
C9ORF72
amyotrophic
lateral
sclerosis/frontotemporal
dementia
(ALS/FTD).
These
repeat
expansion
mutations
can
produce
Nature Neuroscience,
Год журнала:
2018,
Номер
21(2), С. 228 - 239
Опубликована: Янв. 4, 2018
The
cytoplasmic
mislocalization
and
aggregation
of
TAR
DNA-binding
protein-43
(TDP-43)
is
a
common
histopathological
hallmark
the
amyotrophic
lateral
sclerosis
frontotemporal
dementia
disease
spectrum
(ALS/FTD).
However,
composition
aggregates
their
contribution
to
process
remain
unknown.
Here
we
used
proximity-dependent
biotin
identification
(BioID)
interrogate
interactome
detergent-insoluble
TDP-43
found
them
enriched
for
components
nuclear
pore
complex
nucleocytoplasmic
transport
machinery.
Aggregated
disease-linked
mutant
triggered
sequestration
and/or
nucleoporins
factors,
interfered
with
protein
import
RNA
export
in
mouse
primary
cortical
neurons,
human
fibroblasts
induced
pluripotent
stem
cell-derived
neurons.
Nuclear
pathology
present
brain
tissue
cases
sporadic
ALS
those
involving
genetic
mutations
TARDBP
C9orf72.
Our
data
strongly
implicate
TDP-43-mediated
defects
as
mechanism
ALS/FTD.
Annual Review of Pathology Mechanisms of Disease,
Год журнала:
2018,
Номер
14(1), С. 1 - 27
Опубликована: Авг. 8, 2018
Among
the
age-dependent
protein
aggregation
disorders,
nine
neurodegenerative
diseases
are
caused
by
expansions
of
CAG
repeats
encoding
polyglutamine
(polyQ)
tracts.
We
review
clinical,
pathological,
and
biological
features
these
inherited
disorders.
discuss
insights
into
pathogenesis
gleaned
from
studies
model
systems
patients,
highlighting
work
that
informs
efforts
to
develop
effective
therapies.
An
important
conclusion
analyses
is
expanded
CAG/polyQ
domains
primary
drivers
neurodegeneration,
with
biology
carrier
proteins
influencing
disease-specific
manifestations.
Additionally,
it
has
become
apparent
repeat
produce
neurodegeneration
via
multiple
downstream
mechanisms,
involving
both
gain-
loss-of-function
effects.
This
indicates
likelihood
developing
therapies
targeting
single
nodes
reduced.
The
evaluation
treatments
for
premanifest
disease
will
likely
require
new
investigational
approaches.
highlight
opportunities
challenges
underlying
ongoing
provide
recommendations
related
development
symptomatic
disease-modifying
biomarkers
could
inform
future
research.